Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral OKN-007 in recurrent high-grade glioma
NCT05561374Phase 1Active, not recruiting
- Sponsor
- Oblato, Inc.
- Start
- Apr 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of OKN-007 in glioma, Oligodendroglioma (OG), astrocytoma and 1 more (4 arms), sponsored by Oblato, Inc. Primary endpoints: Safety and Tolerability (Adverse Events), Maximum Plasma Concentration and 3 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
OKN-007
03
Conditions
gliomaOligodendroglioma (OG)astrocytomaglioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05561374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561374.